Renata Medical is using proceeds from a recent $25 million Series D round to accelerate U.S. commercialization of its heart valve stent designed for pediatric patients.
The round was led by Archimed, a private equity firm in France focused on healthcare, with participation from existing investors. The funds will also support entry into international markets, pipeline development and further clinical studies
“The support and participation of Archimed is further validation of what we are building and of the growing opportunity to transform care for children with congenital heart disease,” Chief Executive Dustin Armer said in a statement.
Armer said that adoption of the Minima Stent
Armer said that adoption of the Minima Stent has “exceeded” expectations since it launched shortly after getting FDA premarket approval in 2024. Last August, the Centers for Medicare & Medicaid Services (CMS) granted the device a new technology add-on payment designation, incentivizing hospitals to adopt the technology through additional reimbursement.
Prior to the recent round, Renata reportedly raised approximately $29 million to date, including an undisclosed Series C round that helped fund the commercialization of Minima.
Post-Approval Studies
Newport Beach-based Renata was co-founded in 2019 by Armer and Eason Abbott, two former R&D engineers from Edwards Lifesciences Corp. Abbott also serves as chief operating officer.
The stent they developed for congenital heart disease
The stent they developed for congenital heart disease earned them the Business Journal’s Innovator of the Year Awards last year. It’s the first and only FDA-approved stent specifically tailored for neonates, infants and young children that expands in size as they age and grow.
Since beginning commercialization, Renata has published six-month results from a multicenter pivotal trial evaluating Minima in pediatric patients with narrowed pulmonary arteries or aorta.
The study found that the stent was successfully implanted in 41 of 42 patients, relieving narrowing without any serious device-related side effects or need for surgery.
Renata also presented two-year follow up data
Renata also presented two-year follow up data from the Minima Stent Growth Trial at the 2025 Pediatric and Congenital Interventional Cardiovascular Society Symposium in Chicago.
Taps Interventional Cardiologist From Cedars-Sinai as CMO
Renata has also made a key addition to its leadership team.
The company in January appointed Dr. Evan Zahn, a pediatric interventional cardiologist from Cedars-Sinai Medical Center, as chief medical officer.
He is not only a world-class clinician
“He is not only a world-class clinician and innovator, but also a trusted voice whose work has influenced standards of care across the globe,” Armer said. “His decision to join Renata full-time reflects a deep belief in our technology, our team, and our vision for the future of congenital heart care.”
While at Cedars-Sinai, Zahn was the director of a program that treats both children and adults with congenital heart disease.
As chief medical officer of Renata, he will oversee clinical strategy, research and development, medical education and global physician engagement.
